Origin, Challenges, Opportunities, and Mechanisms of Action

Nneoma James,Esther Owusu,Gildardo Rivera,Debasish Bandyopadhyay

DOI: https://doi.org/10.3390/ijms25116285

IF: 5.6

2024-06-08

International Journal of Molecular Sciences

Abstract:Triple-negative breast cancer (TNBC) cells are devoid of estrogen receptors (ERs), progesterone receptor (PRs), and human epidermal growth factor receptor 2 (HER2), and it (TNBC) counts for about 10–15% of all breast cancers. TNBC is highly invasive, having a faster growth rate and a higher risk of metastasis and recurrence. Still, chemotherapy is one of the widely used options for treating TNBC. This study reviewed the histological and molecular characterization of TNBC subtypes, signaling pathways that are aberrantly expressed, and small molecules targeting these pathways, as either single agents or in combination with other therapeutic agents like chemotherapeutics, immunotherapeutics, and antibody–drug conjugates; their mechanisms of action, challenges, and future perspectives were also reviewed. A detailed analytical review was carried out using the literature collected from the SciFinder, PubMed, ScienceDirect, Google Scholar, ACS, Springer, and Wiley databases. Several small molecule inhibitors were found to be therapeutics for treating TNBC. The mechanism of action and the different signaling pathways through which the small molecules exert their effects were studied, including clinical trials, if reported. These small molecule inhibitors include buparlisib, everolimus, vandetanib, apatinib, olaparib, salidroside, etc. Some of the signaling pathways involved in TNBC, including the VEGF, PARP, STAT3, MAPK, EGFR, P13K, and SRC pathways, were discussed. Due to the absence of these biomarkers, drug development for treating TNBC is challenging, with chemotherapy being the main therapeutic agent. However, chemotherapy is associated with chemoresistance and a high toxicity to healthy cells as side effects. Hence, there is a continuous demand for small-molecule inhibitors that specifically target several signaling pathways that are abnormally expressed in TNBC. We attempted to include all the recent developments in this field. Any omission is truly unintentional.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the treatment challenges for triple - negative breast cancer (TNBC). Specifically, TNBC cells lack estrogen receptors (ERs), progesterone receptors (PRs) and human epidermal growth factor receptor 2 (HER2), which makes TNBC highly invasive, with a fast growth rate and a high risk of metastasis and recurrence. Due to the absence of these biomarkers, drug development for TNBC faces enormous challenges. Chemotherapy remains the main treatment method, but chemotherapy has side effects such as drug resistance and high toxicity to healthy cells.

Therefore, this review article aims to explore and summarize the research progress of small - molecule therapeutic agents in TNBC, especially those small - molecule drugs that can target abnormally expressed signaling pathways. The article analyzes in detail the mechanisms of action of these small - molecule drugs, the challenges they face and their future development prospects, and reviews relevant clinical trial data. Through this series of studies, the author hopes to provide new ideas and methods for the treatment of TNBC in order to improve the treatment effect and reduce side effects.